In a candid, unscripted exchange, India’s pharma titans peeled back the mythology of overnight success to reveal a harder truth: conviction compounded over decades. What began as two products and a bet on neglected therapy areas evolved into a multibillion-dollar enterprise riding India’s epidemiological shift. Innovation, they argued, is a long game—scarred by failed trials, investor backlash, and capital droughts—yet redeemed by landmark deals and scientific persistence. In this episode, host Vikas Dandekar talks to Dilip Shanghvi, Chairman of Sun Pharma and Glenn Saldanha, Managing Director at Glenmark Pharma about regulatory reforms, AI acceleration, and a renewed policy push, the message was clear: India stands at the cusp of a pharmaceutical inflection point—if it dares to back its pipeline as boldly as its past.
Listen on:
Listen to Corner Office Conversation: Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with Elizabeth Reid, Head of Search, Google, Corner Office Conversation with Rajan Anandan, Managing Director, Peak XV & Surge and much more.
Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.
See omnystudio.com/listener for privacy information.
